Pharming Group N.V. ADS each representing 10 ordinary shares (PHAR)
Stock · NASDAQ · Health Care
$9.36as of 10/16/2026
Price chart
Active signals
PHAR Signal Track Record
How signals performed across all stocks →What PHAR's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Bollinger Band Breakdown | 24 | +6.5% | 67% | September 29, 2026 |
| Bollinger Band Breakout | 22 | -1.7% | 45% | June 30, 2026 |
| 200-Day Moving Average TouchActive now | 22 | +2.1% | 64% | March 13, 2026 |
| Volume Spike | 9 | -3.1% | 44% | September 16, 2026 |
| Any 20-session window (baseline) | -0.7% | 48% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About PHAR
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company's lead product is RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniol…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 407
- Website
- www.pharming.com/
Fundamentals
- 1-day range
- $9.31$9.52
- Market cap
- $766.28M
- P/E (trailing)
- 73.41
- P/E (forward)
- 30.33
- EPS (trailing)
- $0.02
- Dividend yield
- —
- Beta
- -0.04
- Avg. volume
- 23.0K
Forecasts
4 analyst ratings
Pharming Group N.V. ADS each representing 10 ordinary shares Competitors
Chosen by industry and closest market cap.
- PHARPharming Group N.V. ADS each representing 10 ordinary shares$9.36▼ 2.80%Market cap $766.28MP/E 73.41$0.8338$1.82
- CYRXCryoPort Inc. Common Stock$16.84▼ 1.35%Market cap $741.42MP/E —$7.61$18.36
- DRUGBright Minds Biosciences Inc. Common Stock$51.3▼ 5.37%Market cap $792.81MP/E —$68.02$170
- CTMXCytomX Therapeutics Inc. Common Stock$2.28▼ 5.39%Market cap $733.66MP/E —$2.2$8.21
- RIGLRigel Pharmaceuticals Inc. Common Stock$45.97▼ 2.71%Market cap $732.62MP/E 2.76$24.95$52.24
- CLYMClimb Bio Inc. Common Stock$9.82▼ 9.99%Market cap $801.68MP/E —$1.64$18.33
- MNPRMonopar Therapeutics Inc. Common Stock$69.27▼ 3.52%Market cap $805.29MP/E —$50.07$124.82
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| PHAR Pharming Group N.V. ADS each representing 10 ordinary shares | $766.28M | 73.41 | $9.36 | ▼ 2.80% | $0.8338$1.82 |
| CYRX CryoPort Inc. Common Stock | $741.42M | — | $16.84 | ▼ 1.35% | $7.61$18.36 |
| DRUG Bright Minds Biosciences Inc. Common Stock | $792.81M | — | $51.3 | ▼ 5.37% | $68.02$170 |
| CTMX CytomX Therapeutics Inc. Common Stock | $733.66M | — | $2.28 | ▼ 5.39% | $2.2$8.21 |
| RIGL Rigel Pharmaceuticals Inc. Common Stock | $732.62M | 2.76 | $45.97 | ▼ 2.71% | $24.95$52.24 |
| CLYM Climb Bio Inc. Common Stock | $801.68M | — | $9.82 | ▼ 9.99% | $1.64$18.33 |
| MNPR Monopar Therapeutics Inc. Common Stock | $805.29M | — | $69.27 | ▼ 3.52% | $50.07$124.82 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Pharming Says Leniolisib Reduced Spleen Volume In 10 Of 11 Evaluable Participants And Lymph Node Size In All 4 In Phase II Genetic PID Trial, With No New Safety Signalsbenzinga · 10/14/2026
- Pharming Group: Viable Contrarian Buy If Ruconest StabilizesSeekingAlpha · 9/30/2026
- Pharming announces CEO transitionYahoo · 9/29/2026
- Pharming announces U.S. FDA acceptance and Priority Review of sNDA for lower doses of Joenja® to treat children with APDSYahoo · 9/25/2026
- HC Wainwright & Co. Reiterates Buy on Pharming, Maintains $37 Price TargetBenzinga · 9/22/2026
- Pharming announces positive Phase II topline data for leniolisib in PIDs with immune dysregulation accepted as late-breaking abstract at ESID 2026Yahoo · 9/22/2026
- Pharming Group (PHAR) Expands Joenja’s Pediatric Label. Can Growth Offset RUCONEST Weakness?Yahoo · 9/16/2026
- Pharming Group N.V. (PHAR) Presents at H.C. Wainwright 28th Annual Global Investment Conference - SlideshowSeekingAlpha · 9/14/2026
- HC Wainwright & Co. Reiterates Buy on Pharming, Maintains $37 Price TargetBenzinga · 9/14/2026
Institutional Ownership
March 31, 2026
- Total shares held
- 82.8K
- Total value held
- $1.38M
- Institutional holders
- 11
- Unknown44.7K
- Unknown11.5K
- Unknown10.8K
- Unknown10.2K
- Unknown4.1K
- Unknown557
- Unknown400
- Unknown343
- Unknown128
- Unknown79
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 25, 2026
Pharming Reports Positive Phase II Data; Analysts Maintain Target
Pharming Group announced that the Phase II study of leniolisib in patients with primary immunodeficiency disorders produced positive topline results, presented as a late‑breaking abstract at the ESID 2026 conference. The data support the drug’s potential to address immune dysregulation. In related news, HC Wainwright & Co. reiterated its support for the company and kept its $37 price target unchanged. These developments may influence investor perception of Pharming’s pipeline and valuation.
Pharming Reports Positive Phase II Data; Analysts Maintain Target. Pharming Group announced that the Phase II study of leniolisib in patients with primary immunodeficiency disorders produced positive topline results, presented as a late‑breaking abstract at the ESID 2026 conference. The data support the drug’s potential to address immune dysregulation. In related news, HC Wainwright & Co. reiterated its support for the company and kept its $37 price target unchanged. These developments may influence investor perception of Pharming’s pipeline and valuation.